Low fat dietary intervention with ω-3 fatty acid supplementation in multiple sclerosis patients

Results: 31 RRMS patients were enrolled, with mean follow up over 11±SD 2.9 months. Clinical benefits favoring the FO group were observed on PCS/SF-36 (P=0.050) and MHI (P=0.050) at 6 months. Reduced fatigue was seen on the OO diet at 6 months (P=0.035). The relapse rate decreased in both groups relative to the rates during the 1 year preceding the study: mean change in relapse rate in the FO group: −0.79±SD 1.12 relapses/year (P=0.021) vs. −0.69±SD 1.11 (P=0.044) in the OO group. This study suggests that a low fat diet supplemented with ω-3 PUFA can have moderate benefits in RRMS patients on concurrent disease modifying therapies.